Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer — Yahoo · 2026-10-27
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 — Benzinga · 2026-10-27
Daiichi Sankyo Company, Limited (DSNKY) stock price, news, quote and history — Yahoo Finance Singapore · 2026-10-22
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO — Yahoo · 2026-10-22
Tormere — informational purposes only, not investment advice.